Kinetic mechanism for p38 MAP kinase α: A partial rapid-equilibrium random-order ternary-complex mechanism for the phosphorylation of a protein substrate

FEBS Journal

Volumn 272, Issue 18, 2005, Pages 4631-4645

  Szafranska, Anna E ^a   Dalby, Kevin N ^a  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

Author keywords

Docking; Inhibition; Kinetic mechanism; MAP kinase; p38 MAPK

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE DIPHOSPHATE; ADENOSINE DIPHOSPHATE MAGNESIUM; ADENOSINE TRIPHOSPHATASE (MAGNESIUM); BETA,GAMMA METHYLENEADENOSINE TRIPHOSPHATE; MAGNESIUM; MITOGEN ACTIVATED PROTEIN KINASE 14; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; DISSOCIATION CONSTANT; DRUG INHIBITION; ENZYME BINDING; ESCHERICHIA COLI; INHIBITION KINETICS; KINETICS; MICROCALORIMETRY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; STEADY STATE;

ACTIVATING TRANSCRIPTION FACTOR 2; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ANIMALS; CALORIMETRY; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; DIPHOSPHONATES; ENZYME INHIBITORS; KINETICS; MICE; MULTIPROTEIN COMPLEXES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTEINS; TRANSCRIPTION FACTORS;

ESCHERICHIA COLI;

EID: 25444489311     PISSN: 1742464X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2005.04827.x     Document Type: Article

References (46)

1. Pearson G, Robinson F, Beers Gibson T, Xu BE, Karandikar M, Berman K & Cobb MH (2001) Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions. Endocrin Rev 22, 153-183.
2. Schultz RM (2003) Potential of p38 MAP kinase inhibitors in the treatment of cancer. Prog Drug Res 60, 59-92.
3. Kumar S, Boehm J & Lee JC (2003) p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov 2, 717-726.
4. Blease K, Lewis A & Raymon HK (2003) Emerging treatments for asthma. Expert Opin Emerg Drugs 8, 71-81.
5. Dong C, Davis RJ & Flavell RA (2002) MAP kinases in the immune response. Annu Rev Immunol 20, 55-72.
6. Wang Z, Harkins PC, Ulevitch RJ, Han J, Cobb MH & Goldsmith EJ (1997) The structure of mitogen-activated protein kinase p38 at 2.1-A resolution. Proc Natl Acad Sci USA 94, 2327-2332.
7. Wilson KP, Fitzgibbon MJ, Caron PR, Griffith JP, Chen W, McCaffrey PG, Chambers SP & Su MS (1996) Crystal structure of p38 mitogen-activated protein kinase. J Biol Chem 271, 27696-27700.
8. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, Brown ML & Pargellis CA (1997) A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol 4, 311-316.
9. Wang Z, Canagarajah BJ, Boehm JC, Kassisa S, Cobb MH, Young PR, Abdel-Meguid S, Adams JL & Goldsmith EJ (1998) Structural basis of inhibitor selectivity in MAP kinases. Structure 6, 1117-1128.
10. Wilson KP, McCaffrey PG, Hsiao K, Pazhanisamy S, Galullo V, Bemis GW, Fitzgibbon MJ, Caron PR, Murcko MA & Su MS (1997) The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase. Chem Biol 4, 423-431.
11. Pargellis C, Tong L, Churchill L, Cirillo PF, Gilmore T, Graham AG, Grob PM, Hickey ER, Moss N, Pav S et al. (2002) Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site. Nat Struct Biol 9, 268-272.
12. Fitzgerald CE, Patel SB, Becker JW, Cameron PM, Zaller D, Pikounis VB, O'Keefe SJ & Scapin G (2003) Structural basis for p38alpha MAP kinase quinazolinone and pyridol-pyrimidine inhibitor specificity. Nat Struct Biol 10, 764-769.
13. Fantz DA, Jacobs D, Glossip D & Kornfeld K (2001) Docking sites on substrate proteins direct extracellular signal-regulated kinase to phosphorylate specific residues. J Biol Chem 276, 27256-27265.
14. Shearrocks AD, Yang SH & Galanis A (2000) Docking domains and substrate-specificity determination for MAP kinases. Trends Biochem Sci 25, 448-453.
15. Biondi RM & Nebreda AR (2003) Signalling specificity of Ser/Thr protein kinases through docking-site-mediated interactions. Biochem J 372, 1-13.
16. Boskovic DS, Troxler T & Krishnaswamy S (2004) Active site-independent recognition of substrates and product by bovine prothrombinase: a fluorescence resonance energy transfer study. J Biol Chem 279, 20786-20793.
17. Wilkens M & Krishnaswamy S (2002) The contribution of factor Xa to exosite-dependent substrate recognition by prothrombinase. J Biol Chem 277, 9366-9374.
18. Boskovic DS & Krishnaswamy S (2000) Exosite binding tethers the macromolecular substrate to the prothrombinase complex and directs cleavage at two spatially distinct sites. J Biol Chem 275, 38561-38570.
19. Baugh RJ, Dickinson CD, Ruf W & Krishnaswamy S (2000) Exosite interactions determine the affinity of factor X for the extrinsic Xase complex. J Biol Chem 275, 28826-28833.
20. Betz A & Krishnaswamy S (1998) Regions remote from the site of cleavage determine macromolecular substrate recognition by the prothrombinase complex. J Biol Chem 273, 10709-10718.
21. Krishnaswamy S & Betz A (1997) Exosites determine macromolecular substrate recognition by prothrombinase. Biochemistry 36, 12080-12086.
22. Bergstrom RC, Coombs GS, Ye S, Madison EL, Goldsmith EJ & Corey DR (2003) Binding of non-physiological protein and peptide substrates to proteases: differences between urokinase-type plasminogen activator and trypsin and contributions to the evolution of regulated proteolysis. Biochemistry 42, 5395-5402.
23. Stanley TB, Wu SM, Houben RJ, Mutucumarana VP & Stafford DW (1998) Role of the propeptide and gamma-glutamic acid domain of factor IX for in vitro carboxylation by the vitamin K-dependent carboxylase. Biochemistry 37, 13262-13268.
24. Waas WF, Lo HH & Dalby KN (2001) The kinetic mechanism of the dual phosphorylation of the ATF2 transcription factor by p38 mitogen-activated protein (MAP) kinase alpha. Implications for signal/response profiles of MAP kinase pathways. J Biol Chem 276, 5676-5684.
25. LoGrasso PV, Frantz B, Rolando AM, O'Keefe SJ, Hermes JD & O'Neill EA (1997) Kinetic mechanism for p38 MAP kinase. Biochemistry 36, 10422-10427.
26. Chen G, Porter MD, Bristol JR, Fitzgibbon MJ & Pazhanisamy S (2000) Kinetic mechanism of the p38-alpha MAP kinase: phosphoryl transfer to synthetic peptides. Biochemistry 39, 2079-2087.
27. Szafranska AE, Luo X & Dalby KN (2005) Following in vitro activation of mitogen-activated protein kinases by mass spectrometry and tryptic peptide analysis: purifying fully activated p38 MAP kinase alpha. Anal Biochem 336, 1-10.
28. Segel IH (1993) Enzyme Kinetics. Wiley, New York.
29. Lee JC, Laydon JT, McDonnell PC, Gallagher TF, Kumar S, Green D, McNulty D, Blumenthal MJ, Keys JR, Landvatter SW et al. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372, 739-746.
30. Saklatvala J, Rawlinson L, Waller RJ, Sarsfield S, Lee JC, Morton LF, Barnes MJ & Farndale RW (1996) Role for p38 mitogen-activated protein kinase in platelet aggregation caused by collagen or a thromboxane analogue. J Biol Chem 271, 6586-6589.
31. Thurmond RL, Wadsworth SA, Schafer PH, Zivin RA & Siekierka JJ (2001) Kinetics of small molecule inhibitor binding to p38 kinase. Eur J Biochem 268, 5747-5754.
32. McGovern SL, Caselli E, Grigorieff N & Sheoichet BK (2002) A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening. J Med Chem 45, 1712-1722.
33. McGovern SL & Shoichet BK (2003) Kinase inhibitors: not just for kinases anymore. J Med Chem 46, 1478-1483.
34. McGovern SL, Helfand BT, Feng B & Shoichet BK (2003) A specific mechanism of nonspecific inhibition. J Med Chem 46, 4265-4272.
35. Ladbury JE & Chowdhry BZ (1996) Sensing the heat: the application of isothermal titration calorimetry to thermodynamic studies of biomolecular interactions. Chem Biol 3, 791-801.
36. Fabbro D & Garcia-Echeverria C (2002) Targeting protein kinases in cancer therapy. Curr Opin Drug Discov Dev. 5, 701-712.
37. Prowse CN, Deal MS & Lew J (2001) The complete pathway for catalytic activation of the mitogen-activated protein kinase, ERK2. J Biol Chem 276, 40817-40823.
38. Waas WF & Dalby KN (2003) Physiological concentrations of divalent magnesium ion activate the serine/threonine specific protein kinase ERK2. Biochemistry 42, 2960-2970.
39. Waas WF & Dalby KN (2002) Transient protein-protein interactions and a random-ordered kinetic mechanism for the phosphorylation of a transcription factor by extracellular-regulated protein kinase 2. J Biol Chem 277, 12532-12540.
40. Waas WF, Rainey MA, Szafranska AE & Dalby KN (2003) Two rate-limiting steps in the kinetic mechanism of the serine/threonine specific protein kinase ERK2: a case of fast phosphorylation followed by fast product release. Biochemistry 42, 12273-12286.
41. Fox T, Fitzgibbon MJ, Fleming MA, Hsiao HM, Brummel CL & Su MS (1999) Kinetic mechanism and ATP-binding site reactivity of p38gamma MAP kinase. FEBS Lett 461, 323-328.
42. Tanoue T & Nishida E (2003) Molecular recognitions in the MAP kinase cascades. Cell Signal 15, 455-462.
43. Chang CI, Xu BE, Akella R, Cobb MH & Goldsmith EJ (2002) Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol Cell 9, 1241-1249.
44. Lee T, Hoofnagle AN, Kabuyama Y, Stroud J, Min X, Goldsmith EJ, Chen L, Resing KA & Ahn NG (2004) Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry. Mol Cell 14, 43-55.
45. Khokhlatchev A, Xu S, English J, Wu P, Schaefer E & Cobb MH (1997) Reconstitution of mitogen-activated protein kinase phosphorylation cascades in bacteria. Efficient synthesis of active protein kinases. J Biol Chem 272, 11057-11062.
46. Gill SC & von Hippel PH (1989) Calculation of protein extinction coefficients from amino acid sequence data. Anal Biochem 182, 319-326.